From Financial Modeling Prep: 2025-05-07 12:10:00

On May 5, 2025, Marjorie Taylor Greene purchased shares of AbbVie Inc. (NYSE:ABBV) in a transaction ranging between $1,001 and $15,000. AbbVie is a major player in the pharmaceutical industry, known for its presence in immunology, oncology, and neuroscience, and its acquisition of Allergan, maker of Botox, in 2020.

AbbVie and Johnson & Johnson (JNJ) are top U.S. pharmaceutical companies expecting 2025 to be pivotal with increased sales and profits. AbbVie’s expansion into aesthetics and J&J’s diversified business model, including cardiovascular and infectious disease drugs, position them uniquely in the market.

The current price of ABBV is $188.67, up $1.52 or 0.81%, trading between $186.89 and $189.09 today. Over the past year, ABBV has ranged from $153.58 to $218.66, with a market capitalization of around $333.75 billion, showcasing its industry influence.

Today, ABBV traded 1,734,317 shares, indicating active investor interest. With AbbVie’s strategic moves in aesthetics and strong pipeline, investors seeking growth opportunities in the pharmaceutical sector may find it a compelling option. Examining fundamentals, growth potential, and challenges is key in deciding between companies like AbbVie and Johnson & Johnson.



Read more at Financial Modeling Prep:: Marjorie Taylor Greene Invests in AbbVie Inc. (NYS…